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Résumé en
anglais
Cystic Fibrosis (CF) newborn screening (NBS) has been controversial for many
years in France; the long term benefit on pulmonary function test is not yet
demonstrated but its median term benefits on nutritional parameters are
established as soon as the CF screened infant follow-up is done in a specialized
centre. In 2003, the French association “Vaincre La Mucoviscidose” published
recommendations addressed at CRCM concerning post-neonatal screening cystic
fibrosis diagnosis announcement.
Focus:
Taking the French CF neonatal screening program as a case study, we conducted
both a quantitative data survey & a focus groups protocol to gain information on
the attitudes, beliefs, & concerns of professionals about newborn screening (NBS)
& clinical guidelines, this paper points new bioethical issues from the concrete
application of this technology.
Method:
Collective (team) and individual (professionals concerned) interviews in 15 typical
centres (historic centres, low practice centres with limited resources, high practice
centres with considerable resources).
Results:
•  The most important ethical dilemma is the trouble issued of the cystic fibrosis
sickness singularity because: 1) all the children that carry the mutations are not
affected with a severe disease; 2) there is no curative treatment; 3) parents given
information are made anxious, sometimes wrongly if the disease is mild or
asymptomatic.
• The second ethical issue is located in the distinction between two statuses: on
one hand one can observe homozygotes (two mutations), confirmed CF; on the
second hand, one can consider heterozygotes (one mutation) healthy carriers. For
parents of these healthy infants, the period between learning of the screening
result & the sweat test can provoke anxiety, and the long-term impact has not yet
been clearly defined. Parents should receive genetic counselling for future family
planning, to ensure that they understand the concepts of genetic transmission of
CF. (3) However, diagnosis is not always straightforward and difficulties arise
when exhaustive study of the gene, following a borderline sweat test (ST), detects a
mild mutation or a previously unreported mutation of unknown effect.
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